{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:49:30Z","timestamp":1765547370864,"version":"3.44.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Little data exists regarding the optimal antithrombotic strategy during S-ICD implantation to prevent pocket hematomas. This study explores the association between perioperative antithrombotic management and the occurrence of pocket hematoma following S-ICD implantation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>All patients who underwent de novo S-ICD implantation between February 2009 and January 2023 at Amsterdam UMC were included. Data was collected retrospectively from electronic patient records. Clinically significant pocket hematomas were defined as an accumulation of blood at the pocket site within 30\u00a0days after implantation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 347 patients were included of which 224 (64.6%) patients used antithrombotic therapy pre-implantation. The median age at implantation was 50\u00a0years (IQR 36\u201361\u00a0years), 33.4% of the patients were female, and the majority of implants were intermuscular (90.2%). A total of 18 patients (5.2%) developed a clinically significant pocket hematoma. There were significantly more pocket hematomas in patients with continued vitamin K antagonists (VKA) compared to patients with interrupted VKA (27.3% (6\/22) vs. 4.3% (2\/47), respectively, <jats:italic>p<\/jats:italic>\u2009=\u20090.01), and continuation of VKA was an independent predictor for pocket hematoma formation in the VKA group (<jats:italic>p<\/jats:italic>\u2009=\u20090.04). Moreover, continuation of dual antiplatelet therapy (DAPT) with ticagrelor was associated with significantly more pocket hematomas post-implantation compared to continuation of DAPT with clopidogrel (4\/12 vs. 1\/28, respectively, <jats:italic>p<\/jats:italic>\u2009=\u20090.02).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Continuation of VKA during S-ICD implantation was associated with an increased risk of pocket hematoma formation compared to interruption of VKA. This supports the need for specific perioperative antithrombotic therapy guidelines for S-ICD implantations to reduce the risk of pocket hematomas.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s10840-024-01973-x","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T07:29:52Z","timestamp":1737012592000},"page":"1437-1446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antithrombotic therapy and the risk of pocket hematoma after subcutaneous implantable cardioverter-defibrillator implantation"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7530-7048","authenticated-orcid":false,"given":"S.","family":"Pepplinkhuizen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Kors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"de Veld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. A.","family":"Dijkshoorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. R.","family":"Bijsterveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"de Weger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Smeding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A. M.","family":"Wilde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. R. A.","family":"Olde Nordkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. E.","family":"Knops","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"issue":"3","key":"1973_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","volume":"352","author":"GH Bardy","year":"2005","unstructured":"Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225\u201337.","journal-title":"N Engl J Med"},{"issue":"26","key":"1973_CR2","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","volume":"335","author":"AJ Moss","year":"1996","unstructured":"Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933\u201340.","journal-title":"N Engl J Med"},{"issue":"1","key":"1973_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa0909545","volume":"363","author":"GH Bardy","year":"2010","unstructured":"Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med. 2010;363(1):36\u201344.","journal-title":"N Engl J Med"},{"issue":"47","key":"1973_CR4","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1093\/eurheartj\/ehac496","volume":"43","author":"RE Knops","year":"2022","unstructured":"Knops RE, Pepplinkhuizen S, Delnoy P, Boersma LVA, Kuschyk J, El-Chami MF, et al. Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trial. Eur Heart J. 2022;43(47):4872\u201383.","journal-title":"Eur Heart J"},{"issue":"10","key":"1973_CR5","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1093\/europace\/euv075","volume":"17","author":"AR Sridhar","year":"2015","unstructured":"Sridhar AR, Yarlagadda V, Yeruva MR, Kanmanthareddy A, Vallakati A, Dawn B, Lakkireddy D. Impact of haematoma after pacemaker and CRT device implantation on hospitalization costs, length of stay, and mortality: a population-based study. Europace. 2015;17(10):1548\u201354.","journal-title":"Europace"},{"issue":"11","key":"1973_CR6","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jacc.2016.01.009","volume":"67","author":"V Essebag","year":"2016","unstructured":"Essebag V, Verma A, Healey JS, Krahn AD, Kalfon E, Coutu B, et al. Clinically significant pocket hematoma increases long-term risk of device infection: Bruise control infection study. J Am Coll Cardiol. 2016;67(11):1300\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1973_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/europace\/euv053","volume":"17","author":"KA Polyzos","year":"2015","unstructured":"Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace. 2015;17(5):767\u201377.","journal-title":"Europace"},{"issue":"22","key":"1973_CR8","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1056\/NEJMoa1302946","volume":"368","author":"DH Birnie","year":"2013","unstructured":"Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368(22):2084\u201393.","journal-title":"N Engl J Med"},{"issue":"44","key":"1973_CR9","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1093\/eurheartj\/ehy413","volume":"39","author":"DH Birnie","year":"2018","unstructured":"Birnie DH, Healey JS, Wells GA, Ayala-Paredes F, Coutu B, Sumner GL, et al. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). Eur Heart J. 2018;39(44):3973\u20139.","journal-title":"Eur Heart J"},{"issue":"7","key":"1973_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/europace\/euaa367","volume":"23","author":"H Burri","year":"2021","unstructured":"Burri H, Starck C, Auricchio A, Biffi M, Burri M, D\u2019Avila A, et al. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS). Europace. 2021;23(7):983\u20131008.","journal-title":"Europace"},{"issue":"35","key":"1973_CR11","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","volume":"42","author":"M Glikson","year":"2021","unstructured":"Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427\u2013520.","journal-title":"Eur Heart J"},{"issue":"4","key":"1973_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/CIRCEP.109.917625","volume":"3","author":"IB Kutinsky","year":"2010","unstructured":"Kutinsky IB, Jarandilla R, Jewett M, Haines DE. Risk of hematoma complications after device implant in the clopidogrel era. Circ Arrhythm Electrophysiol. 2010;3(4):312\u20138.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"8","key":"1973_CR13","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.hrthm.2013.05.016","volume":"10","author":"RE Knops","year":"2013","unstructured":"Knops RE, Nordkamp L, de Groot JR, Wilde AAM. Two-incision technique for implantation of the subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2013;10(8):1240\u20133.","journal-title":"Heart Rhythm"},{"issue":"8","key":"1973_CR14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1111\/pace.12665","volume":"38","author":"F Des","year":"2015","unstructured":"Des F, Miracapillo G, Cresti A, Severi S, Airaksinen KE. Pocket hematoma: a call for definition. Pacing Clin Electrophysiol. 2015;38(8):909\u201313.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"12","key":"1973_CR15","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.7326\/M22-1566","volume":"175","author":"JS Healey","year":"2022","unstructured":"Healey JS, Krahn AD, Bashir J, Amit G, Philippon F, McIntyre WF, et al. Perioperative safety and early patient and device outcomes among subcutaneous versus transvenous implantable cardioverter defibrillator implantations: a randomized, multicenter trial. Ann Intern Med. 2022;175(12):1658\u201365.","journal-title":"Ann Intern Med"},{"key":"1973_CR16","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1093\/eurheartj\/ehab921","volume":"43","author":"PD Lambiase","year":"2022","unstructured":"Lambiase PD, Theuns DA, Murgatroyd F, Barr C, Eckardt L, Neuzil P, et al. Subcutaneous implantable cardioverter-defibrillators: long-term results of the Effortless study. Eur Heart J. 2022;43:2037.","journal-title":"Eur Heart J"},{"issue":"4","key":"1973_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.hrthm.2017.11.010","volume":"15","author":"MR Afzal","year":"2018","unstructured":"Afzal MR, Mehta D, Evenson C, Pinkhas D, Badin A, Patel D, et al. Perioperative management of oral anticoagulation in patients undergoing implantation of subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2018;15(4):520\u20133.","journal-title":"Heart Rhythm"},{"issue":"7","key":"1973_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/pace.13349","volume":"41","author":"SH Sheldon","year":"2018","unstructured":"Sheldon SH, Cunnane R, Lavu M, Parikh V, Atkins D, Reddy YM, et al. Perioperative hematoma with subcutaneous ICD implantation: impact of anticoagulation and antiplatelet therapies. Pacing Clin Electrophysiol. 2018;41(7):799\u2013806.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"8","key":"1973_CR19","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/pace.13754","volume":"42","author":"C Evenson","year":"2019","unstructured":"Evenson C, Saour B, Afzal MR, Knight B, Okabe T, Weiss R. Increased risk of hematoma with uninterrupted warfarin in patients undergoing implantation of subcutaneous implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 2019;42(8):1111\u20134.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"5","key":"1973_CR20","first-page":"833","volume":"111","author":"JY Le Heuzey","year":"2014","unstructured":"Le Heuzey JY, Ammentorp B, Darius H, De Caterina R, Schilling RJ, Schmitt J, et al. Differences among Western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost. 2014;111(5):833\u201341.","journal-title":"Thromb Haemost."},{"issue":"5","key":"1973_CR21","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.3390\/molecules26051425","volume":"26","author":"D Menichelli","year":"2021","unstructured":"Menichelli D, Poli D, Antonucci E, Cammisotto V, Testa S, Pignatelli P, et al. Comparison of anticoagulation quality between acenocoumarol and warfarin in patients with mechanical prosthetic heart valves: insights from the nationwide Plectrum study. Molecules. 2021;26(5):1425.","journal-title":"Molecules"},{"issue":"6","key":"1973_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.20452\/pamw.709","volume":"119","author":"A Undas","year":"2009","unstructured":"Undas A, Cie\u015bla-Dul M, Z\u00f3\u0142ci\u0144ski M, Tracz W. Switching from acenocoumarol to warfarin in patients with unstable anticoagulation and its effect on anticoagulation control. Pol Arch Med Wewn. 2009;119(6):360\u20135.","journal-title":"Pol Arch Med Wewn"},{"issue":"6","key":"1973_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.hrthm.2010.02.018","volume":"7","author":"I Ahmed","year":"2010","unstructured":"Ahmed I, Gertner E, Nelson WB, House CM, Dahiya R, Anderson CP, et al. Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation. Heart Rhythm. 2010;7(6):745\u20139.","journal-title":"Heart Rhythm"},{"issue":"7","key":"1973_CR24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2459\/JCM.0000000000000011","volume":"16","author":"M Crosato","year":"2015","unstructured":"Crosato M, Calzolari V, Franceschini Grisolia E, Daniotti A, Baldessin F, Mantovan R, Olivari Z. Implanting cardiac rhythm devices during uninterrupted warfarin therapy: a prospective, single center experience. J Cardiovasc Med (Hagerstown). 2015;16(7):503\u20136.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"3","key":"1973_CR25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1540-8159.2004.00441.x","volume":"27","author":"MC Giudici","year":"2004","unstructured":"Giudici MC, Paul DL, Bontu P, Barold SS. Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy. Pacing Clin Electrophysiol. 2004;27(3):358\u201360.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"7","key":"1973_CR26","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1540-8159.2011.03049.x","volume":"34","author":"HK Li","year":"2011","unstructured":"Li HK, Chen FC, Rea RF, Asirvatham SJ, Powell BD, Friedman PA, et al. No increased bleeding events with continuation of oral anticoagulation therapy for patients undergoing cardiac device procedure. Pacing Clin Electrophysiol. 2011;34(7):868\u201374.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"4","key":"1973_CR27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.hrthm.2010.12.016","volume":"8","author":"A Cheng","year":"2011","unstructured":"Cheng A, Nazarian S, Brinker JA, Tompkins C, Spragg DD, Leng CT, et al. Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial. Heart Rhythm. 2011;8(4):536\u201340.","journal-title":"Heart Rhythm"},{"issue":"1","key":"1973_CR28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.dmpk.2019.10.005","volume":"35","author":"E Goto","year":"2020","unstructured":"Goto E, Horinaka S, Ishimitsu T, Kato T. Factor Xa inhibitors in clinical practice: comparison of pharmacokinetic profiles. Drug Metab Pharmacokinet. 2020;35(1):151\u20139.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1973_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jacep.2023.08.037","volume":"10","author":"A Creta","year":"2023","unstructured":"Creta A, Ventrella N, Earley MJ, Finlay M, Sporton S, Maclean E, et al. DOACs vs vitamin K antagonists during cardiac rhythm device surgery: a multicenter propensity-matched study. JACC Clin Electrophysiol. 2023;10:121.","journal-title":"JACC Clin Electrophysiol"},{"issue":"4","key":"1973_CR30","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/europace\/euad028","volume":"25","author":"GL Botto","year":"2023","unstructured":"Botto GL, Ziacchi M, Nigro G, D\u2019Onofrio A, Dello Russo A, Francia P, et al. Intermuscular technique for implantation of the subcutaneous implantable defibrillator: a propensity-matched case-control study. Europace. 2023;25(4):1423\u201331.","journal-title":"Europace"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-024-01973-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-024-01973-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-024-01973-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T18:01:58Z","timestamp":1757959318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-024-01973-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["1973"],"URL":"https:\/\/doi.org\/10.1007\/s10840-024-01973-x","relation":{},"ISSN":["1572-8595"],"issn-type":[{"type":"electronic","value":"1572-8595"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"19 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Springer Nature\u2019s version of this paper was updated: In the original version of this article, the given and family name of L. R. A. Olde Nordkamp was incorrectly structured. The name was displayed correctly in all versions at the time of publication.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Data was collected retrospectively and the need for informed consent was waived by our local Medical Ethics Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.E.K. reports consultancy fees and research grants from Abbott, Boston Scientific, Medtronic, and Cardiac and has stock options from AtaCor Medical Inc. N.R.B. presented at a conference of Abbott and gave a presentation sponsored by AstraZeneca. A.A.M.W is a consultant for ARMGO and Thryv-therapeutics, unpaid.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}